BioPorto
1.48
DKK
-1.99 %
Less than 1K followers
BIOPOR
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Investor consensus
-1.99%
+0.95%
-2.89%
-4.52%
-17.78%
+17.46%
+8.52%
-33.38%
-37.88%
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read moreMarket cap
672.91M DKK
Turnover
114.98K DKK
Revenue
36.24M
EBIT %
-208.2 %
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 15.04.2025
Financial calendar
8.5
2025
Interim report Q1'25
15.8
2025
Interim report Q2'25
19.11
2025
Interim report Q3'25
All
Research
Webcasts
Press releases
ShowingAll content types
Bioporto (One-pager): Capital secured via private placement
Dagens aktienyheder 15/04: ExpreS2ion Biotechnologies og BioPorto A/S
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Bioporto: Rettet emission på 25 mio. aktier fuldtegnet
Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S
Correction: Rettet emission af 25.000.000 nye aktier fuldt tegnet – bruttoprovenu på 33,5 mio. kr. til BioPorto A/S
Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S
Rettet emission af 25.000.000 nye aktier fuldt tegnet – bruttoprovenu på 33,5 mio. kr. til BioPorto A/S
Bioporto: Rettet emission på 25 mio. nye aktier
BioPorto A/S indleder en rettet emission af op til 25.000.000 nye aktier til markedskurs. Bestyrelsen har modtaget forhåndsindikationer for det fulde udbud, som forventes at tilvejebringe et provenu på 33,5 mio. kr.
BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.
Resolutions of the Annual General Meeting
Forløb af den ordinære generalforsamling
Bioporto - Præsentation af Q1 2025
Updated biographies for board candidates at the upcoming Annual General Meeting
Opdaterede biografier for bestyrelseskandidater på den kommende ordinære generalforsamling
Dagens aktienyheder 21.03.2025: Bioporto, Pharma Equity Group, Flügger Group og Windowmaster
Bioporto: Wrap up fra interview med CEO Peter M. Eriksen og CFO Niels H. Nielsen
Bioporto - Præsentation af helårsregnskabet for 2024
